Table 2.

Short-term efficacy of bevacizumab-containing treatment on MPE

Clinical outcomes	Bev + Cis via IP	Bev via IP	Cis via IP	Bev via I.V
	n = 11	n = 4	n = 3	n = 1
CR	0	0	0	0
PR	3	2	2	1
SD	6	0	0	0
PD	2	2	1	0
ORR (%)	81.82	50.00	66.67	100.00

MPE, malignant pleural effusion; Bev, bevacizumab; Cis, cisplatin; IP, intrapleural perfusion; I.V, intravenous injection; complete remission (CR) was considered when the pleural fluid had disappeared and was stable for at least four weeks; partial remission (PR) was considered when >50% of the pleural fluid had disappeared, symptoms had improved, and the remaining fluid had failed to increase for at least four weeks; remission not obvious (NC) was considered when <50% of the accumulated fluid had disappeared; progression disease (PD) was considered when the accumulated fluid had increased. The overall response rate (ORR) was calculated by taking the sum of CR and PR.